Sara A. Hurvitz, MD @dgsomucla @UCLAHealth #SABCS21 #DESTINYBreast03 #BreastCancer #Cancer #Research Phase III DESTINY-Breast03 Trial

Sara A. Hurvitz, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA speaks about the SABCS 2021 Abstract – GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.

Link to Abstract:
https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4